New CEO: SEC was warm-up for ACCME

Share this article:
As John Connolly settles into his new post as president & CEO of M|C Communications, he may find certain experiences from his past especially useful.

Compliance is one area. Connolly was formerly president and CEO of Institutional Shareholder Services (ISS), manager of proxy voting and other corporate governance tasks for public companies.

In an interview, the new CEO drew comparisons between Securities and Exchange Commission (SEC) requirements in his previous business and those of the Accreditation Council for Continuing Medical Education in the CME business, saying his “appreciation and skill set” for compliance will serve him well in his new role.

So will being in the spotlight and talking with the media.

“ISS was on CNBC 20 times in the last 24 months while I was there,” Connolly recalled.
He takes over the position from John Mooney, who will remain chairman, the company said. Mooney, having led M|C Communications for 13 years, stepped down to spend more time with his family, including a three-year-old daughter.

M|C Communications produces the Pri-Med Conference & Exhibitions, one of the largest series of educational meetings aimed at primary care physicians. In 2008, the company forecasts over 150,000 US MDs will attend its sessions, 350,000 globally.

Pri-Med already runs a group of smaller conferences and symposia called Updates, as well as med ed programs for psychiatrists, pharmacists, cardiologists and neurologists.

It plans to launch into other markets, including oncology, soon, Connolly said. Its big, live confabs aimed at GPs will also see more interactivity, with programming delivered on digital devices.

In 1989 Connolly started publishing firm Course Technology, which he sold two years later to Thomson and became CEO of Thomson Media.

Before that, he held senior posts with publishers Lippincott Williams and Wilkins and the educational group of Addison-Wesley.

Share this article:

Email Newsletters

More in News

Eli Lilly and BI's Jardiance hits shelves

Eli Lilly and BI's Jardiance hits shelves

The new SGLT-2 inhibitor is on shelves less than a month after FDA approval.

PhRMA Urges Court to Reject Off-Label Promotion Case

PhRMA Urges Court to Reject Off-Label Promotion Case

The Pharmaceutical Research and Manufacturers of America (PhRMA) says a California federal court should dismiss a whistleblower's False Claims Act suit against three drug companies on First Amendment grounds

Five things for Pharma Marketers to know: Tuesday, August 26

Five things for Pharma Marketers to know: Tuesday, ...

Merck and Pfizer pursue new pembrolizumab research, black box warnings are linked to fewer court visits, and the WHO says it needs $430M to fight Ebola.